Uber, Lyft, Pinterest, Slack among those planning to list or actively considering it, but in comparison to the past the numbers of assets being acquired is low
China will ring in the New Year with brand new PI guidance that takes effect January 1. The rules were published just days before a Fuzhou court’s high-profile injunctions against Apple
A summary of the major IP news from the biotechnology, pharmaceutical and medical technology sectors in November and the first-half of December
Decision of the District Court of Munich orders Apple "to cease the sale, offer for sale and importation for sale in Germany of infringing iPhones" and could be spur to settlement talks
The decision in Monsanto’s appeal against the revocation of a key patent right could have profound implications on the ability to protect agro-biotech inventions in India
IAM uncovers the patents-in-suit, runs down the two sides’ validity wins and losses so far, and provides much more analysis of yesterday's shock preliminary injunction in the Intermediate People's Court of Fuzhou
This year's event in Shanghai has now come to an end. It's been a great couple of days, including the IP Asia Elite Gala Dinner and Awards held last night
How Chinese courts will rule the patent world; Qualcomm's 5G licensing spree; don't jail trolls, says former supreme court judge; patent sales are on the up; plus a whole lot more from a wet, but spectacular, Shanghai Pudong
Your essential Sunday reading: a summary of all the stories posted on the IAM platform in the past week - as well as links to each one
Previous FRAND-related rulings indicate judges in China could set a global rate, would adopt the hard-edged non-discrimination obligation and would consider the parties' negotiation behaviours when reaching their decisions
There is not much time left to make nominations for the 2019 edition of IAM Strategy 300, our exclusive guide on the world's best IP strategists.
TCL v Ericsson and Unwired Planet v Huawei send two very different messages to auto companies being approached by patent pools such as Avanci to take SEP licences, says Unified Patents' chief IP counsel Jonathan Stroud
Life sciences IP is on the front line as American consumers, legislators and the Trump administration kick back against the high cost of medicines. Reform campaigners say they have never been more confident of change.
Exclusive analysis done by ROL Group for IAM shows a maturing market in which prices are stabilising, selling programmes are becoming more streamlined and there are more transactions overall